Myriad Genetics

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Myriad Genetics reports robust Q4 growth and eyes market expansion

Myriad Genetics showcased strong revenue growth and strategic initiatives to drive profitability in Q4 2022.
The company's focus on customer engagement, product volumes, and market positioning reflects a commitment to growth and operational excellence.
Challenges in managing competition and optimizing operational efficiency are balanced by opportunities for revenue growth and market expansion.

Myriad Genetics reports strong Q1 earnings, eyes profitability in Q4

Myriad Genetics demonstrated robust performance in Q1, leveraging strategic partnerships and operational improvements to drive revenue growth and enhance testing volumes.
While facing challenges like billing issues and seasonality-related declines, the company remains focused on core products, profitability, and growth opportunities.
With a strong financial outlook, emphasis on innovation, and commercial initiatives, Myriad Genetics is well-positioned to capitalize on market opportunities and drive sustainable growth.

Myriad Genetics reports solid Q2 growth and strategic focus

Myriad Genetics showcased strong financial performance, operational efficiencies, and strategic focus on growth and profitability.
While facing challenges like milestone payment concerns and industry competition, the company's strengths in key segments and operational capabilities position them well.
Opportunities in product enhancements, channel expansions, and investor engagement pave the way for continued success and market leadership.

Myriad Genetics reports strong Q3 earnings and raises 2024 guidance

Myriad Genetics reported strong revenue growth and operational improvements, with a focus on key product lines and enhancing customer experience.
The company raised financial guidance for 2023 and introduced revenue guidance for 2024, showcasing confidence in achieving long-term growth targets.
Challenges include regulatory changes, market penetration, and maintaining profitability amidst competitive dynamics, while opportunities lie in sustained growth and revenue optimization.
Overall, Myriad Genetics demonstrated resilience and strategic focus in driving growth, improving margins, and navigating market challenges effectively.

Myriad Genetics reports strong Q4 performance and eyes market expansion

Myriad Genetics delivered a strong Q4 performance with a focus on growth, strategic investments, and operational improvements. The company faces challenges in pricing and reimbursement but sees opportunities in market expansion and new product launches. Overall, Myriad Genetics is optimistic about its future prospects and market positioning.

Myriad Genetics reports robust Q1 performance and eyes growth opportunities

Myriad Genetics delivered a strong quarter with revenue growth and positive EBITDA, focusing on strategic areas like oncology and women's health. The company is optimistic about exceeding guidance but remains cautious. Analysts raised inquiries about various segments and operational decisions, with the company emphasizing profitable growth and maintaining margins.

Myriad Genetics reports strong Q2 performance and raises revenue targets

Myriad Genetics delivered a robust Q2 performance with revenue growth, positive earnings, and strategic wins in payer coverage, setting the stage for continued growth.
The company's focus on efficiency, customer satisfaction, and profitable growth positions it well for future success amidst market challenges and opportunities.
With raised revenue targets, expanded market acceptance, and operational excellence, Myriad Genetics demonstrates resilience and adaptability in a dynamic healthcare landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?

Why Is Myriad (MYGN) Down 6.4% Since Last Earnings Report?

The results of the studies will provide a major breakthrough for Myriad Genetics (MYGN) in the field of breast cancer diagnosis and treatment.

Myriad Genetics Announces Study Results Of myRisk Cancer Test

Genomic Health

Invitae

Wall Street soured on the high-growth industry after first-quarter earnings were reported, but it may have been an overreaction for two stocks.

Here's Why Genetic Testing Stocks Lost as Much as 26.1% in May

Myriad Genetics' (MYGN) collaboration with AstraZeneca garners several regulatory go-aheads for BRACAnalysis CDx test.

Myriad Genetics' (MYGN) POLO Study Shows Positive Results

Investor confidence is still high on growth prospects of Myriad Genetics (MYGN).

Why Should You Hold on to Myriad Genetics (MYGN) Stock?

The genetic testing pioneer lost $500 million in value after reporting fiscal Q3 operating results.

Myriad Genetics Reduced 2019 Guidance, but Is It Really So Bad?

Livent Corp

Marathon Petroleum

These stocks struggled on a mixed day on Wall Street.

Why Marathon Petroleum, Livent, and Myriad Genetics Slumped Today

Myriad Genetics (MYGN) observes strong year-over-year revenue growth in EndoPredict, Hereditary Cancer and Prolaris testing as well as pharmaceutical and clinical service segments.

Myriad Genetics (MYGN) Q3 Earnings Top Estimates, Revenues Up

Myriad Genetics, Inc. (MYGN) CEO Mark Capone on Q3 2019 Results - Earnings Call Transcript

Myriad Genetics, Inc. (MYGN) CEO Mark Capone on Q2 2019 Results - Earnings Call Transcript

Myriad (MYGN) delivered earnings and revenue surprises of 4.55% and -0.81%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Myriad Genetics (MYGN) Beats Q3 Earnings Estimates

bluebird bio

Bristol-Myers

Celgene

CRISPR Therapeutics

Editas Medicine

Guardant Health Inc

Gilead Sciences

Illumina

Novartis

Spark Therapeutics

Pacific Biosciences of California

REGENXBIO

Roche Holding AG

Thermo Fisher Scientific

These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.

Top Gene-Sequencing Stocks for 2019

The expanded partnership will help Myriad Genetics boost top-line contributions in the near term.

Myriad Genetics Expands CDx Tie Up With AstraZeneca & Merck

The recent development will help Myriad Genetics to boost top-line contributions from prenatal tests.

Myriad Genetics New Study Data to Lift Prenatal Tests' Uptake

NeoGenomics

Quarterly earnings from around the industry suggested the epic growth opportunity isn't slowing down anytime soon.

Here's Why Genetic Testing Stocks Rose as Much as 42.9% in February

News for Myriad Genetics Stock (MYGN)